Laos vs Rwanda: Average cost of drugs for extensively drug-resistant tuberculosis
Laos
1,250 constant 2022 US$
in 2024
Rwanda
1,483 constant 2022 US$
in 2024
Laos rank
37th
Rwanda rank
35th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Laos
- Rwanda
How they compare
Rwanda currently reports 1,483 constant 2022 US$ against 1,250 constant 2022 US$ in Laos, a difference of 233 constant 2022 US$.
That makes Rwanda's figure about 1.2 times Laos's.
Across all 7 years both countries report, Rwanda has been ahead every year.
Laos ranks 37th and Rwanda ranks 35th of 56 countries.
Rwanda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Laos | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,250 constant 2022 US$ | 4,380 constant 2022 US$ | 3,130 constant 2022 US$ | Rwanda |
| 2020s | 1,240 constant 2022 US$ | 3,070 constant 2022 US$ | 1,830 constant 2022 US$ | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Laos or Rwanda?
- Rwanda, at 1,483 constant 2022 US$ against 1,250 constant 2022 US$ in Laos as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Laos and Rwanda?
- 233 constant 2022 US$, with Rwanda ahead.
- How many years of comparable data are there for Laos and Rwanda?
- 7 years are reported by both, from 2018 to 2024.
- How do Laos and Rwanda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Laos ranks 37th and Rwanda ranks 35th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.